Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.46 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18725422 | 1.00 | CNR1 (0.47) | CNR1CHRM1CNR2PDE2APDE11A | |
| SCHEMBL18725420 | 1.00 | CNR1 (0.47) | CNR1CHRM1CNR2PDE2APDE11A | |
| SCHEMBL12803280 | 0.78 | CNR2 (0.43) | CNR1CHRM1CNR2 | |
| SCHEMBL18725444 | 0.77 | CNR1 (0.52) | CNR1CHRM1CNR2ANO1 | |
| SCHEMBL18725447 | 0.77 | CNR1 (0.52) | CNR1CHRM1CNR2ANO1 | |
| SCHEMBL18725446 | 0.77 | CNR1 (0.52) | CNR1CHRM1CNR2ANO1 | |
| SCHEMBL18725393 | 0.73 | LIPE (0.40) | GABRA1USP30 | |
| SCHEMBL12074157 | 0.71 | CHRM1 (0.39) | CHRM1PDE2APDE11AGABRA1 | |
| SCHEMBL15051210 | 0.70 | ABL1 (0.46) | — | |
| SCHEMBL626900 | 0.69 | L3MBTL1 (0.44) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CNR1 27/4885CHRM1 1/4885CNR2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.